The common negative hits in all of the performed CRISPR-Cas9 screens included members of the menin-MLL1 complex (ASH2L, KMT2A, and MEN1), PRC1/PRC2 complexes (CBX4, EED, EZH2, and SUZ12), chromatin remodelers (ARID1A, BAZ2A, CHD2, and SMARCC2), acetyl- and deacetyl-transferases (BRPF3, CCDC101, HDAC7, KAT6A, KAT7, and MGEA5), transcriptional activators or repressors (RRP8, SAFB, TADA1, TADA3, TEAD3, and TRIM33), and other hits (ASF1A, BRCA1, GSG2, RAD54L, UHRF1, and VRK1) and represent potential targets for primary HCC (Figure 1E). This evidence concerns the gene SMARCC2 and hepatocellular carcinoma.